Skip to main content
SNY
NASDAQ Life Sciences

赛诺菲的Rezurock获得欧盟有条件批准，用于治疗慢性移植物抗宿主病

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$46.6
Mkt Cap
$113.575B
52W Low
$43.32
52W High
$55.995
Market data snapshot near publication time

summarizeSummary

赛诺菲已从欧洲委员会获得Rezurock (belumosudil) 的有条件上市授权，用于治疗12岁及以上成年人和儿童的慢性移植物抗宿主病（GVHD）。此次批准是在2026年1月30日欧洲药品管理局CHMP发表积极意见后，并在2026年2月6日的6-K文件中提到的“欧盟Rezurock批准”之后，表明市场已经有一定程度的预期。这一授权扩大了Rezurock进入欧盟市场的机会，加上其在美国、英国、加拿大和中国的现有批准，解决了患者有限的治疗选择这一重大未满足的医疗需求。有条件的性质需要完成确认性研究，这将是观察完全授权的关键因素。

在该公告发布时，SNY的交易价格为$46.60，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1135.8亿。 52周交易区间为$43.32至$56.00。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed SNY - Latest Insights

SNY
Apr 29, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Prices €2.3 Billion Multi-Tranche Bond Issue for General Corporate Purposes
Sentiment: Neutral
View Wiseek Article
SNY
Apr 27, 2026, 12:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Secures Key FDA Approvals for Dupixent and Tzield, Despite Sarclisa Delay
Sentiment: Positive
View Wiseek Article
SNY
Apr 24, 2026, 6:09 AM EDT
Source: GlobeNewswire
Importance Score:
8
EU Regulators Recommend Sanofi's Cenrifki for Secondary Progressive MS Approval
Sentiment: Positive
View Wiseek Article
SNY
Apr 23, 2026, 7:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Strong Q1 Double-Digit Sales & EPS Growth, Multiple Regulatory Approvals, and Pipeline Advancements
Sentiment: Positive
View Wiseek Article
SNY
Apr 18, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability in Head-to-Head Study
Sentiment: Positive
View Wiseek Article
SNY
Apr 15, 2026, 6:57 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Positive Phase 2 Lunsekimig Data and EU Approval for Dupixent in Young Children with CSU
Sentiment: Positive
View Wiseek Article
SNY
Apr 07, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Sanofi's Lunsekimig Meets Phase 2 Endpoints in Asthma and CRSwNP, Bolstering Respiratory Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 12:19 PM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Reports Positive Phase 3 Amlitelimab Data for Atopic Dermatitis, Advances Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Rezurock Secures EU Conditional Approval for Chronic Graft-vs-Host Disease
Sentiment: Positive
View Wiseek Article
SNY
Mar 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
CHMP Recommends EU Approval for Sanofi's Innovative Sarclisa On-Body Injector for Multiple Myeloma
Sentiment: Positive
View Wiseek Article